TBX3 and ulnar-mammary syndrome: Importantly, while mutations resulting in reduced levels of TBX3 give rise to the ulnar mammary syndrome, high levels of TBX3 expressed postnatally impact several oncogenic processes including bypassing senescence and apoptosis, promoting substrate‐dependent and independent cell proliferation, cell migration and invasion and in vivo tumour‐forming ability [7].